Download presentation
Presentation is loading. Please wait.
Published bySiv Jansson Modified over 6 years ago
1
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease Fevzi F. Yalniz, Mehrdad Hefazi, Kristen McCullough, Mark R. Litzow, William J. Hogan, Robert Wolf, Hassan Alkhateeb, Ankit Kansagra, Moussab Damlaj, Mrinal M. Patnaik Biology of Blood and Marrow Transplantation Volume 23, Issue 9, Pages (September 2017) DOI: /j.bbmt Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
2
Figure 1 Outcomes at 4, 8, and 12 weeks after the initiation of infliximab therapy. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
3
Figure 2 Organ-specific responses at 12 weeks after the initiation of infliximab therapy. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.